Le Lézard
Classified in: Health, Science and technology
Subjects: NPT, SVY, POL, AVO

Wireless Radiation Can Cause Cancer-Expert Panel Reviewing $25 Million NTP, NIEHS Study Concludes


WASHINGTON, March 30, 2018 /PRNewswire/ -- California Brain Tumor Association announces the National Toxicology Program Review Panel has concluded that there is CLEAR EVIDENCE of a rare heart cancer being caused by cell phone radiation in a $25 million National Institute of Environmental Health Sciences animal study completed over 18 years (NTP website: https://ntp.niehs.nih.gov/about/org/sep/trpanel/meetings/index.html)

With the NTP study results supporting the findings of human studies, we have enough scientific evidence to increase the classification of all wireless radiation from a Class 2B (possible carcinogen) to a Class 1 Human Carcinogen (carcinogenic to humans) like cigarette smoke and asbestos; therefore, we should be warning the public of harm and minimizing our exposure not maximizing exposure as we are doing with the forced roll out of 5G and the Internet of Things.

The heart cancer finding is critical because the rarity of this cancer shows the very carcinogenic effect of wireless radiation.  It is also important because the rarity of the cancer shows that the cancer was definitely caused by the wireless radiation.  Most importantly, the type of cells that became cancerous were the same type of cells found to cause tumors in human studies of cell phone radiation exposure showing an increase in Acoustic Neuromas (tumors of the ear) found in earlier human studies.  In addition last week The Ramazzini Institute released the largest rat study of its kind focused on exposures from cell towers with levels of wireless RF radiation exposures 60-1000 times lower than the levels tested in the NTP study; importantly, they also found the same type of heart cancer resulting from wireless RF radiation exposure: https://www.ncbi.nlm.nih.gov/pubmed/29530389.

The industry controlled FCC and Congress who is well funded by the telecom industry should be held responsible for not warning the public of this cancer risk since we have had the human studies for years and the World Health Organization classified all wireless radiation as a Class 2B Carcinogen in 2011.  The FCC and Congress need to be held accountable for last week passing The Wireless Infrastructure Streamlining Order and The Ray Baum Act which specifically bans any consideration of scientific and environmental evidence like the critical findings of the NTP Study and Ramazzini Institute Study when placing a 5G cell tower transmitter near unsuspecting residents homes.

For more information regarding the review panels findings please see:  http://bit.ly/NTPpanel2a

Contact for more info regarding this press release:

Kevin Mottus
Outreach Director
CA Brain Tumor Association 
Email: [email protected]

SOURCE California Brain Tumor Association


These press releases may also interest you

at 06:05
AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March 25-31 as National Physicians Week. This week and throughout the year, we celebrate the dedication of physicians who selflessly...

at 06:00
The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to  ResearchAndMarkets.com's...

at 05:45
The "Global Proteomic Biomarker Analytics Market Forecasts by Application, Technology, Product, and Place, with Executive & Consultant Guides; Including Customized Forecasting and Analysis" report has been added to  ResearchAndMarkets.com's offering....

at 05:45
The Gross Law Firm issues the following notice to shareholders of InMode Ltd. . Shareholders who purchased shares of INMD during the...

at 05:30
The "Syndromic Multiplex Panels Markets. Strategies and Trends. Forecasts by Syndrome (Respiratory, Sepsis, GI etc.) by Place, by Product and by Country. With Market Analysis and Executive Guides. 2024 to 2028" report has been added to...

at 05:20
IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced that China National Medical Products Administration (NMPA) has approved the...



News published on and distributed by: